In 2024, we acquired the physician outreach business of OhioHealth, of University Hospitals, two big, large healthcare systems in Ohio. We acquired the physician outreach business of Allina Health towards the end of 2024 as well, or in 2024. Those have allowed us to gain share in the market, and we continue to see the benefit of that this year as well. We will do more of those acquisitions as they come up, again, strategically, where we have good access, but maybe not as much capture as we would like.
Those are generally accretive relatively quickly, I bet.
Absolutely, yeah. There are some integration costs at the front end. You have to get the systems to integrate between the health system and our systems. But within a short period of time, they get to our enterprise margins.
Then, maybe just thinking about the hospital channel and Co-Lab, I know it is a billion-dollar kind of plus business. You talked about getting to $2 billion, I think over the next couple years. Can you just talk to the funnel as it relates to new customers, and how do new customer wins contribute to growth versus just expansion with existing accounts?
Yeah, it's definitely an active funnel. I mean, we started this business back in around 2016 or so, really from nothing, and we built this business. Really, just for the audience here, the business is about running the inpatient lab of a health system, of a hospital, where we take over the lab and we provide savings and benefits in terms of guaranteed savings to the hospital. We get also some savings as well, or benefits, I should say, on running that lab. So we have a guaranteed margin. They have a certain amount of savings that they get. Corewell was a big Co-Lab partnership that we onboarded this year. It's about 20+ hospitals that we run their inpatient lab. The funnel is very active in terms of these partnerships.
I think more and more, as hospitals require the support and the help of large independent labs like us, they turn to us for savings, for basically personnel savings or savings on their cost of employees, savings on their cost of procurement, on their contracts with different vendors, and we can help them gain synergies on that. The funnel is active. I think we've got a good set of potential partnerships that we have an eye towards.
Obviously, a lot of people focus on kind of some of the hospital pressures, ACA reform. I guess, are you seeing an acceleration in those conversations?
To some extent. I mean, the funnel has been pretty vibrant, I would say, or healthy, both in terms of Co-Lab partnerships and physician outreach acquisitions for some time. But listen, as these pressures, they're definitely not abating. I mean, these pressures are escalating for health systems, whether it's the healthcare exchange subsidies being eliminated, whether it's Medicaid work eligibility requirements driving more uninsured patients into their care, sometimes patients that can't pay. We are in a, I would say, a privileged position as Quest to have the scale, to have the means, the ability, the financial strength to be able to support the hospitals and support patients as well. So, that is something that's definitely that we're focused on. Yes, I mean, I think these conversations are increasing.
How do you think about the margin profile? I know Corewell and Fresenius have come in below corporate margins. You are doing some reinvestment there. At maturity, can Co-Lab approach corporate margins?
Co-Lab is—h ere is the thing about Co-Lab. The margins are always going to be, in terms of at least margin rate, are always going to be less than our enterprise margins. If our enterprise margins today are somewhere around 16%, 17% operating margin rate, Co-Lab will be somewhere in the low double digits, maybe in the either low teens or 12%-13% margin rates. But the thing about Co-Lab is virtually very little capital deployment. The return on invested capital is really high on those businesses. So, I am less concerned about margin rate on Co-Lab, more concerned about shareholder return and ROIC and how we can generate return on invested capital. It is a very, very attractive profile in terms of return on invested capital on those businesses.
Now, to your question about Corewell, for instance, when we onboard those businesses, and with Corewell, we onboarded a very large Co-Lab relationship, $250 million approximately of revenues in 2026. Usually, you start out at lower margins until you can get the relationship set up, get past the integration costs, and then you start to see the margins improve, which is what we are seeing with Corewell right now.
I think, Co-Lab versus buying outreach, you talked last quarter, obviously, you acquired some outreach assets from a longtime Co-Lab customer. How do you think about the trade-offs there between running a hospital lab through Co-Lab versus just owning the outreach book of business?
Yeah, I like to think of it, Tycho, as an and, not an or. Both are really accretive for us as a business. As I said, there are a lot of ways that we can support our health system partners, and we can either support them by running their inpatient lab as a Co-Lab relationship, where, as I said earlier, we can guarantee them certain savings, get some return as a result as well, or we can purchase that physician outreach book of business from them, which is what we've done with the examples that I gave around OhioHealth, University Hospitals. The way that physician outreach works is you have a health system that has basically affiliated physicians that send their lab work to the hospital.
For the same reasons that a hospital decides to let us run their inpatient lab, they decide that labs is just not a strategic area for them. They have this opportunity to sell their physician outreach business to an independent, large independent lab like us. They monetize that. They get a capital injection to support some of their other strategic goals and their growth aspirations, and that lab work automatically transfers to us, where now the patients basically get sent to either our patient service centers and the testing gets done in a Quest lab. Or, in-office phlebotomist at a physician office draws the blood and the physician sends the work to Quest. It's a pretty easy lift and shift in terms of moving that volume to a Quest lab.
Okay. PAMA, you talked about a 1% potential revenue hit if it goes through. I guess, is there still a path in your view for RESULTS, after reform, and then what milestones should we be watching between now and year-end?
Yeah. I'm sure a lot of the people here have heard about PAMA and what PAMA entails, and it's the Protecting Access to Medicare Act. We've just recently had a data collection. Data collection results were shared, where CMS came out and said, "If we basically reinstate the cuts as of January 1, they'll get $1 billion of savings." Again, I want to emphasize, we believe the data collection, again, was flawed, similar to what we saw back in 2017. The participation in this data collection was essentially almost 80%, 77% to be exact, from the large independent labs. 77% of the test volume was really provided by the large independent labs. 10% of the test volume was submitted by the health system. Again, doesn't take much to figure out that the average, the weighted median is being largely influenced by the independent lab submission.
What we would like to see is a more representative data collection methodology that is provided by a third-party agency. Here is what the RESULTS Act does. The RESULTS Act basically mandates that you would have a third-party agency that does the data collection, and you would have a suspension of these cuts until 2029, at which time, based on an independent data collection agency, the cuts would not exceed 5%. You would have a cap of 5% on the cuts, and potentially a price increase if the data were to bear that out. Now, to your question around what is the potential path? First of all, there needs to be a CBO, Congressional Budget Office scoring of the RESULTS Act. We expect that that will happen this month.
On that basis, then there is a determination in terms of the cost, the pay for, and how does that compare versus the $1 billion that was identified by CMS as savings next year if PAMA were to come back into effect. We have about 140 members of Congress, bipartisan representation, that essentially are ready to sponsor and are sponsoring the RESULTS Act. There is an appetite for price reform, because I think there is a recognition that the data collection methodology is just not accurate. It is flawed. Now, to get the RESULTS Act passed, it needs to be part of a healthcare legislation by the end of the year, unless there is some type of an extension, a continuing resolution that goes into next year. But there needs to be a broader bill upon which the RESULTS Act gets essentially included.
Whether that happens, I mean, honestly, I would not put odds on it. It is a wait and see. We are pushing for it. We are lobbying with the help of ACLA, which is the industry lobby, to get the RESULTS Act passed. There is a potential and there is an option that PAMA could be delayed again, or it could come back at the beginning of 2027.
Okay. You have talked about, I think the bulk of the hit would be in 2027, right? Is that kind of 1% and then less than 1.3% through 2029, so kind of a tail after?
Yeah. Here's the thing I want to emphasize. I mean, if PAMA does get reinstated at the beginning of 2027, we do expect to see a 1% cut to our Medicare pricing. Medicare is about 8% of our business. So we've sized that impact as about 1% of our overall revenues. We said that there would be a follow-on impact of about 30 basis points between 2028 and 2029. So to your point, the magnitude is mostly felt in 2027. I do want to emphasize a couple of things. One, we will offset a portion of the 2027 hit and cut. It won't be the majority of it, but there will be a portion that we will offset through cost reductions, other initiatives that we take, other actions that we take to offset that margin hit.
But at the same time, I want to emphasize, that's the second thing I want to make sure I mention, is that this is an impact that will be felt on our Medicare pricing, and otherwise, the business does not really get impacted by any of this PAMA noise. The business is healthy, utilization is strong, our pricing dynamics are favorable, our revenue per requisition is positive. So, the business is really strong, and this is, I would say, a ring-fenced impact across our Medicare business.
And I know you've gotten the question in the past, for smaller independent labs, outreach programs, maybe it means more consolidation, right? More opportunities. Are you seeing that in your discussions now, or are these labs kind of waiting and seeing how it plays out?
I wouldn't say necessarily we're seeing cause-effect as a result of PAMA, where more are immediately coming to the table to talk about potential consolidation, sale, et cetera. But it definitely will add pressure to some of the independent labs, especially the smaller ones. It'll add pressure to community hospitals. I mean, 8% of our business is in Medicare. Some community hospitals have a larger portion of their business sitting in Medicare, and they will feel that impact in a meaningful way. And we are well-positioned. We have the financial means. We have the ability to withstand that impact. And frankly, it's not going to change anything that we do in our business in terms of long-term strategy and focus and investments. But I can't say the same about some of the other smaller players that will feel this.
Yes, it might force them to have to take a look at other options because they cannot remain viable.
You flagged consumer earlier, that is going to grow over 30% this year. I guess, how much of that is QuestHealth versus your partnerships, and how do you think about kind of the longer-term growth rate of that business as it sits?
Yeah. Let me just make sure that I explain our consumer business, which is still a small portion of our overall business. It is still less than 3% of our overall business, but growing fast, growing over 30% to the point that you mentioned. That business, which is now annualizing, let us call it over $300 million in terms of annual revenues, is about 25%-30% is our direct consumer business. So it is an e-commerce website that you go to, that you purchase a test, you get that test. You go to a patient service center, you get your blood drawn, you get a result after a day, shows up in your MyQuest app, and gives you insights about depending on the test that you did.
The other 65%-70% of that business is us being the engine and really the partner to a lot of these wellness companies, wearable companies, including Apple Health that we basically formed a partnership with. In September, we announced that partnership, or they announced the partnership, where you can order lab testing directly from an app. So it is a digital interface, and we support that through, again, the same concept. A patient comes to our PSC, gets the test fulfilled, the test result gets passed on, and then they see that result either as part of a comprehensive report through a company like a Function Health or a Hone Health, or maybe a Hims & Hers, or they see it in the app as part of more insights that basically reconcile their biometrics with their biomarkers to give them more insight about their health.
With a company like Apple, you go on your Apple Health app, you order a test, it is a panel of about 50 biomarkers, and you get the results in your Apple Health app.
Is that bringing new people under the channel, or do you think it is diverting people that would have gone through the physician office normally?
I think honestly it is two different things. I mean, you have the people that go into their GP, they do their annual physical, or they have certain preexisting conditions or certain comorbidities, and they will do testing, and that gets covered by their insurance, by their third-party payer, and they work through a physician. You have this new generation and a lot of Gen Zs and others that are more, let us just say, more proactive about their overall health, whether it is because they want peak performance because they are athletes or they are really concerned about how their biometrics, again, reconcile with their biomarkers to get a better true picture of their overall health.
Again, with Gen Zs, there is a lot of motivation to just interact digitally. I do not want to go to my physician. I do not have a physician to begin with. I do not know who my GP is.
I do not want to deal with a payer, I just want to order a test through my app, get the result there, and really get a good overall picture of my health. I think it is two customer segments, frankly. It is two patient segments, and we are seeing a good accretive benefit from this consumer business.
Haystack MRD, you have the DYNAMIC work, you have good analytical and clinical data now. I guess, how do we think about what is going to ultimately drive commercial volume here? Is it guidelines, reimbursement, sales force optimization?
Yeah. Just to orient everybody, Haystack Oncology is the minimal residual disease test that we acquired back in 2023. We consider it a best-in-class test in terms of sensitivity and basically the ability to detect recurring tumor, circulating tumor in the blood. So it is a liquid biopsy test for both baseline and then recurrence monitoring. We have been getting, to your question, Tycho, we have been getting good traction on this test, increase in terms of the number of tests that are performed each week. Having said this, we have paced our commercial adoption, and the reason we have paced our commercial efforts, I should say, which drives adoption. The reason we have paced our commercial efforts is a couple of things. One is mainly reimbursement. We do not want to do a bunch of tests that we do not get reimbursed for.
We are currently working with MolDX on getting Medicare Advantage Reimbursement. We have PLA codes that have been priced, the baseline at $3,900, the recurrence at $800. We are performing testing, obviously, but we are pacing our efforts to make sure that we do not do a whole bunch of tests that we do not get reimbursed for. The test has gotten very, very good feedback. First of all, we got breakthrough designation with the FDA. We got New York State approval. We had this DYNAMIC study which demonstrated the effectiveness of the test. As I said, we are working with MolDX on getting reimbursement for the test as well.
Got it. Maybe just shifting over to AI and across kind of the enterprise today, at a high level, I guess, how do you think about the opportunities in customer-facing applications, ordering, interpretation, and then inertia and functions like pathology workflows, prior auths?
Sure.
Yeah, lab operations?
Yeah. There are areas in AI which we've been, I would say, immersed in for some time, beyond the sort of agentic AI, large language model adoption that's happened more so in the last two years. We have AI in our labs that has been really critical for improving productivity. Give you some examples. For instance, microbiology, pathology. Those are areas where AI, through algorithms, really helps, whether it's pathologists or lab technicians, understand regions of interest and be able to make more accurate diagnoses, especially in pathology, for instance, and digital cytology are two areas. That helps increase the productivity of pathologists. That really helps to drive better diagnoses. So that's an area that we've been in some time and will continue to expand on that in terms of the operations of our lab. You have the other emerging areas in AI. I call them two areas.
One is more so the data curation and data aspect, and it could be things like route optimization for our logistics team, dynamic route optimization and finding productivity in terms of every day, different routes for our drivers. I mean, we've got drivers that basically circle the globe every day 5x . That's the number of miles that they cover. We've got a number of airplanes that transport samples across the country. So, the more that we can dynamically optimize these routes, it provides productivity. You've got areas that we call the sort of frictionless patient experience and how AI can help in that. One area is the Quest AI Companion on MyQuest results, for instance. If you pull up your results in MyQuest, we have now an agentic AI language model that helps you understand your results better.
You can also, down the road, our plan is to be able to have functionality and portability with other language models outside of the one that we offer, whether it's OpenAI or Gemini or others, where you can move your results into that and be able to curate your results there and ask questions and understand your results. We're looking at other options as well in terms of, or other initiatives, I should say, like, for instance, customer service. We get a lot of calls from providers asking about the results of their patients and whether they're available or not. There's no reason why all that can't be handled by, or at least most of it, by AI agents, and then essentially they can triage those calls depending on whether there's another level of questioning that needs to be handled by a human.
Maybe in the last minute, just, I guess, thinking about the framework for next year, kind of higher level, PAMA, maybe 1% headwind as we talked about, Corewell for Fresenius to annualize those. Utilization's good though, and maybe some uplift on the partnership margins. How are you thinking about the gives and takes for 2027?
Yeah. Here are a lot of the gives in terms of what's strong in our business. Utilization, we expect continued strength in our business. Consumer, I talked about over 30% growth. I won't give you a growth number for next year, but long term, we expect the growth of the consumer business to exceed 20%. When you think about margins, obviously driven by strong utilization, that improves, continues to mean improving margins as well in our business. When you think about, again, physician channel, hospital channel, we expect the same dynamics that we're seeing this year in terms of strength. In terms of other investments that we're making, Project Nova, which is the modernization of our order-to-cash process, that will require more investments next year, as it has required investments this year.
But offsetting that, we have initiatives like Invigorate, which aims to take out 3% of cost and add productivity, which will also be in effect for next year. And finally, one take, I guess, is PAMA, if it happens, is a 1% impact to our business. But the business is performing really well. The utilization's very strong, and we're proud of the progress we've made.
Great. We'll leave it at that. Thanks.
All right. Thank you.